[Abstract] Mol Metab
The health regulator said it had received reports of adverse events, with some requiring hospitalization, that may be related to overdoses due to patients incorrectly self-administering the compounded drug and health-care providers miscalculating doses
North Am
Importantly, GCGR agonist is also associated with increased energy expenditure, a key factor in weight management and metabolic health
When you read that warning label, the language sounds genuinely frightening
[DOI] [PubMed] [Google Scholar] 10.Chiasson J.L., Josse R.G., Gomis R., Hanefeld M., Karasik A., Laakso M., STOP-NIDDM Trial Research Group Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: The STOP-NIDDM trial